Jazz Pharmaceuticals vs United Therapeutics
JAZZ and UTHR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JAZZ and UTHR compare
United Therapeutics is the larger company, worth 1.8 times as much as Jazz Pharmaceuticals ($25.7B against $14.0B).
On earnings, Jazz Pharmaceuticals is cheaper: it trades at 14.8× trailing earnings, against 21.4× for United Therapeutics.
Jazz Pharmaceuticals grew revenue faster over the last twelve months (12.6% versus 2.5% for United Therapeutics).
United Therapeutics keeps more of each dollar of sales as profit, with a net margin of 41.6% compared with 20.4% at Jazz Pharmaceuticals.
Jazz Pharmaceuticals scores higher on the StockData Score (11 against 10 for United Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JAZZ | UTHR |
|---|---|---|
| Size and price | ||
| Market cap | $14.0B | $25.7B |
| Share price | $215.98 | $598.72 |
| Change, 1 year | 59.1% | 31.5% |
| Change, 5 years | 59.9% | 196% |
| Beta (5Y) | 0.55 | 0.54 |
| Employees | 2,890 | 1,400 |
| StockData Score | ||
| Total score | 11 (better) | 10 |
| Valuation score | 4 (better) | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 4 | 5 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 14.8× (better) | 21.4× |
| P/S | 3.0× (better) | 8.1× |
| P/B | 2.9× (better) | 4.0× |
| EV/EBITDA | 18.0× | 15.4× (better) |
| P/FCF | 8.8× (better) | 23.5× |
| PEG | – | 0.93 |
| FCF yield | 11.4% (better) | 4.3% |
| Fair value | $254.92 | $477.00 |
| Margin of safety | 15.3% (better) | −25.5% |
| Growth | ||
| Revenue growth (TTM) | 12.6% (better) | 2.5% |
| Revenue growth, 5Y average | 12.5% | 16.5% (better) |
| Net income growth (TTM) | – | 5.5% |
| EPS growth (TTM) | – | 9.0% |
| EPS growth, 5Y average | – | 19.3% |
| Profitability | ||
| Gross margin | – | 86.1% |
| Operating margin | 19.5% | 44.4% (better) |
| Net margin | 20.4% | 41.6% (better) |
| FCF margin | 34.6% | 34.6% (better) |
| Return on equity | 22.1% (better) | 19.3% |
| Return on invested capital | 12.1% | 29.7% (better) |
| Financial health | ||
| Debt / equity | 0.91 | – |
| Net debt / EBITDA | 2.40 | – |
| Interest coverage | – | 117× |
| Current ratio | 1.78 | 5.73 (better) |
| Altman Z-score | 2.35 | 22.13 (better) |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 9.7% |
| Shareholder yield | 0.00% | 9.7% (better) |
| Ownership | ||
| Held by institutions | 99.2% | 97.4% |
| Held by insiders | 3.4% | 5.9% |
| Insider net buying, 12 months | −$68.0M (better) | −$1.3B |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.7% | 8.9% |
Go deeper
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
- UTHR stock overview
- UTHR income statement
- UTHR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.